Practice of anticoagulation with heparin following acute stroke in Germany: Results from ten centers of the German Stroke Study Collaboration;Praxis der vollheparinisierung nach ischämischem schlaganfall in Deutschland zwischen 1998-2003: Ergebnisse aus zehn zentren des Studienverbundes Schlaganfall

Aktuelle Neurologie

Volumn 31, Issue 8, 2004, Pages 383-388

  Kraywinkel, Klaus ^a   Weimar, C ^a   Busse, O ^b   Haass, A J ^c   Ehrenfeld, C E ^a   Diener, H C ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b KLINIKUM MINDEN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULANT THERAPY; ARTERY DISSECTION; ARTICLE; DRUG INDICATION; DRUG MEGADOSE; GERMANY; HUMAN; PRACTICE GUIDELINE; STROKE; THROMBUS;

EID: 6344223493     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828379     Document Type: Article

References (28)

1. Daffertshofer M, Grips E, Dempfle CE, Hennerici M. Heparin in der Akutphase des ischämischen Schlaganfalls: Datenlage und klinische Realität. Nervenarzt 2003; 74: 307-319
2. Swanson RA. Intravenous heparin for acute stroke: what can we learn from the megatrials? Neurology 1999; 52: 1746-1750
3. Coull BM, Williams LS, Goldstein LB et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Neurology 2002; 59: 13-22
4. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205-1210
5. Deutsche Gesellschaft für Neurologie. Leitlinie "Primäre und sekundä re Prävention der zerebralen Ischämie", http://www.dgn.org/127.0.html 2003; letzter Zugriff 7.6.2004
6. Weimar C, Glahn J, Reutern GM von et al. Behandlung des ischämischen Schlaganfalls in 14 neurologischen Stroke Units. Eine Auswertung der Schlaganfalldatenbank der Stiftung Deutsche Schlaganfallhilfe. Nervenarzt 2002; 73: 342-348
7. German Stroke Study Collaboration. Predicting outcome after acute ischemic stroke: An external validation of prognostic models. Neurology 2004; 62: 581-585
8. Ehrenfeld CE, Kraywinkel K, Weimar C, Diener HC. Langzeitverlauf zerebrovaskulärer Erkrankungen unterschiedlicher Ätiologie. Akt Neurol 2003; S1, Abstract: V132
9. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-1272
10. Al-Sadat A, Sunbulli M, Chaturvedi S. Use of intravenous heparin by North American neurologists: do the data matter? Stroke 2002; 33: 1574-1577
11. Kudesia R, Chaturvedi S. Practice variation among Michigan neurologists in the use of intravenous heparin. J Neurol Sci 2002; 202: 25-27
12. Thomassen L, Brainin M, Demarin V et al. Acute stroke treatment in Europe: a questionnaire-based survey on behalf of the EFNS Task Force on acute neurological stroke care. Eur J Neurol 2003; 10: 199-204
13. Caplan LR. Resolved: Heparin may be useful in selected patients with brain ischemia. Stroke 2003; 34: 230-231
14. Donnan GA, Davis SM. Heparin in stroke: not for most, but the controversy lingers. Stroke 2003; 34: 232-233
15. Sandercock P. Full heparin anticoagulation should not be used in acute ischemic stroke. Stroke 2003; 34: 231-232
16. Hamann GF. Intravenöse Heparintherapie beim akuten ischämischen Hirninfarkt - Contra. Akt Neurol 2001; 28: 122-127
17. Busse O, Haberl R. Intravenöse Heparintherapie beim akuten ischämischen zerebralen Insult: Pro. Akt Neurol 2001; 28: 118-121
18. Chamorro A. Heparin in acute ischemic stroke: the case for a new clinical trial. Cerebrovasc Dis 1999; 9, Suppl 3: 16-23
19. Hacke W, Kaste M, Bogousslavsky J et al. European Stroke Initiative Recommendations for Stroke Management - update 2003. Cerebrovasc Dis 2003; 16: 311-337
20. Adams HP Jr, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056-1083
21. Kay R, Wong KS, Yu YL et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-1593
22. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581
23. Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 2000; 31: 1770-1778
24. Saxena R, Lewis S, Berge E et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333-2337
25. Diener HC, Ringelstein EB, Kummer R von et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001; 32: 22-29
26. Bath PM, Lindenstrom E, Boysen G et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-710
27. Hankey GJ, Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischemic stroke. Stroke 2003; 34: 1571-1572
28. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33: 2722-2727